1Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of<7% without weight gain or hypoglycaemia in type 2 diabetes: a recta-analysis of the liraglutide clinical trial programme[J]. Diabetes Obes Metab, 2012, 14(1): 77-82.
2Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans[J]. J Clin Invest, 1998, 101(3): 515-520.
3Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-l(GLP-l) in obese men[J], lnt J Obes Relat Metab Disord, 1999, 23(3): 304-311.
4Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2[J]. Am J Physiol Regul Integr Comp Physiol, 1999, 276(5 Pt 2): R1541-1544.
5Hoist JJ. The physiology of glucagon-like peptide I [J]. Physiol Rev, 2007, 87(4): 1409-1439.
6Tang-Christensen M, Larsen P J, Goke R, et al. Central administration of GLP-I(7- 36) amide inhibits food and water intake in rats[J]. Am J Physiol, 1996, 271(4 Pt 2): R848-856.
7Buse 3B, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial(LEAD-6)[J]. Lancet, 2009. 374(9683): 39-47.
8Blase E, Taylor K, Gao HY, et al. Pharmacokinetics of an oral drug(acetaminophen) administered at various times in relation to subcutaneous injection of exenatide(exendin-4) in healthy subjects[J]. J Clin Pharmacol, 2005, 45(5): 570-577.
9Kapitza C, Zdravkovic M, Hindsberger C, et al. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen[J]. Adv Ther, 2011, 28(8): 650-660.
10Unger J. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm[J]. J Am Osteopath Assoc, 2011, 111(2Suppl 1): eS2-9.
3DEROAS G,MAFFIOLI P. Efficacy and safety profile evaluationof acarbose alone and in association with other antidiabeticdrugs: asystematic review [J].Clin Ther,2012,34(6) : 1221-1236.
4XU W,BI Y,SUN Z,et al. Comparison of the effects on glycaemicontrol andp-cell function in newly diagnosed type 2 diabetespatient of treatment with exenatide, insulin or pioglitazone : amulticentr randomized parallel-group trial (the CONFIDENCEstudy) [J].J Intern Med, 2015,277( 1) : 137-150.
5PONZANI P. Long-term effectiveness and safety of liraglutide inclinical [ J].Minerva Endocrinologica, 2013,38( 1) : 103-112 .
6KIM YG,HAHNS,OH TJ,et al. Differences in the glucose-lowering efficacy of dipcptidyl peptidase-4 inhibitors betweenAsians and non-Asians ; a systematic review and mcta-analysis[J].Diabetologia, 2013,56(4) :696-678.
7LSHIBASHI Y,NISHIN0 Y,MATSUI T,et al. Glucagon-likepeptide-1 suppresses advanced monocyteche-moattra ctantprotein-1 expression in mesangial cells by reducing advancedglycation end product receptor level [J].Metabolism, 2011,60(9):1271-1277.
8SKOV J,DEJGAARD A,FR KI R J,et al. Glucagon-likepeptide-1 (GLP-1) : effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men [J].J ClinEndocrinol Metab,2013,98(4) :E664-E671.
9EGAN AG,BLIND E,DUNDER K,et al. Pancreatic safety ofincretin-based drugs-FDA and EM A assessmenl [J].N Engl JMed, 2014,370(9):794-797.
10BUISSON M , CORNU C , NONY P. Erroneous event count in ameta-analysis (dipeptidyl peptidase-4 inhibitors in type 2diabetes mellitus) [J].Am J Cardiol,2015,115(6): 852.
